| Summary: | Searching for new drugs for the treatment of influenza is important due to the epidemiological significance of this disease entity, affecting a significant percentage of people around the world. Preventive vaccinations, which significantly improve the overall epidemiological situation in the analyzed population, cannot completely solve the problem, which results from numerous pharmacological and social conditions. Baloxavir marboxil is one of the newest influenza A and B medications approved in Japan (2018), the United States of America (2019) and Australia, Canada and Switzerland (2020). It works by inhibiting a specific viral endonuclease and blocking RNA transcription in the infected cell. A single administration of 40 or 80 mg of the drug up to 48 hours after the onset of symptoms results in a reduction in viral load and the duration of fever and other symptoms of the disease, usually without serious side effects, and can be used in children after dose adjustment according to their weight . The factors limiting the applicability are the price higher than other therapies and the lack of registration in the European Union, which, however, does not exclude the possibility of use.
Searching for new drugs for the treatment of influenza is important due to the epidemiological significance of this disease entity, affecting a significant percentage of people around the world. Preventive vaccinations, which significantly improve the overall epidemiological situation in the analyzed population, cannot completely solve the problem, which results from numerous pharmacological and social conditions. Baloxavir marboxil is one of the newest influenza A and B medications approved in Japan (2018), the United States of America (2019) and Australia (2020). It works by inhibiting a specific viral endonuclease and blocking RNA transcription in the infected cell. A single administration of 40 or 80 mg of the drug up to 48 hours after the onset of symptoms results in a reduction in viral load and the duration of fever and other symptoms of the disease, usually without serious side effects, and can be used in children after dose adjustment according to their weight . The factors limiting the applicability are the price higher than other therapies and the lack of registration in the European Union, which, however, does not exclude the possibility of use.
|
|---|
